Gary Ingenito Sells 12,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Gary Ingenito sold 12,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the sale, the insider now directly owns 51,391 shares in the company, valued at $1,167,603.52. This represents a 18.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock traded down $0.27 during midday trading on Friday, hitting $22.07. 554,323 shares of the company traded hands, compared to its average volume of 1,187,151. The stock has a market cap of $2.63 billion, a price-to-earnings ratio of 18.70, a PEG ratio of 3.44 and a beta of 0.75. The firm’s fifty day moving average price is $21.23 and its 200-day moving average price is $18.72. Catalyst Pharmaceuticals, Inc. has a 12 month low of $13.00 and a 12 month high of $24.27.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in Catalyst Pharmaceuticals by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock worth $127,212,000 after buying an additional 860,244 shares during the period. American International Group Inc. boosted its position in Catalyst Pharmaceuticals by 10.0% during the 1st quarter. American International Group Inc. now owns 60,087 shares of the biopharmaceutical company’s stock worth $958,000 after buying an additional 5,463 shares during the period. Lazard Asset Management LLC boosted its position in Catalyst Pharmaceuticals by 36.6% during the 1st quarter. Lazard Asset Management LLC now owns 30,334 shares of the biopharmaceutical company’s stock worth $482,000 after buying an additional 8,133 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Catalyst Pharmaceuticals by 1.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,219,418 shares of the biopharmaceutical company’s stock worth $19,439,000 after buying an additional 22,860 shares during the period. Finally, California State Teachers Retirement System boosted its position in Catalyst Pharmaceuticals by 4.3% during the 1st quarter. California State Teachers Retirement System now owns 106,357 shares of the biopharmaceutical company’s stock worth $1,695,000 after buying an additional 4,346 shares during the period. 79.22% of the stock is owned by institutional investors.

Analysts Set New Price Targets

CPRX has been the topic of a number of analyst reports. Citigroup increased their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Truist Financial raised their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Finally, Stephens assumed coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an “overweight” rating and a $35.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $31.14.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.